Abstract: FR-PO652
Additional Benefit of Patiromer Under Real-Life Conditions
Session Information
- Fluid and Electrolytes: Clinical - Potassium, Sodium, Water
November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Fluid and Electrolytes
- 902 Fluid and Electrolytes: Clinical
Authors
- Seibert, Eric, Nephrologisches Zentrum, Villingen-Schwenningen, Germany
- Weinreich, Thomas, Nephrologisches Zentrum, Villingen-Schwenningen, Germany
- Ulrich, Christof, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany
- Fiedler, Roman, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany
- Girndt, Matthias, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany
- Reichel, Helmut, Nephrologisches Zentrum, Villingen-Schwenningen, Germany
- Hohenstein, Bernd, Nephrologisches Zentrum, Villingen-Schwenningen, Germany
Background
Patiromer was placed on the market in Germany in April 2018. Additional Benefit was not affirmed by regulatory authorities (GBA-Gemeinsamer Bundesausschuss). In the OPAL-HK trial, in patients that were treated with Patiromer, mean serum potassium levels declined by 1.01±0.03 mmol/L and after 4 weeks 76% of the patients reached potassium levels below 5.1 mmol per liter. We sought to evaluate, whether these promising results can be achieved under real-life conditions outside of clinical trials.
Methods
We analysed potassium levels in all patients treated with patiromer in a large chronic kidney disease cohort including patients with and without renal replacement therapy. In addition, the number of patients that reached the target range below 5.1 mmol/l was evaluated. Data extraction and analysis were performed using an multi-factorial Algorithm-based approach.
Results
7222 Patients that were treated between 1.1.2018 and 15.4.2019 were screened. 49 Patients (20 females) were treated with Patiromer (24 hemodialysis, 2 peritoneal dialysis, 23 CKD). For 37 patients at least one potassium value was available before and after initiation of Patiromer. Mean potassium levels were 5.85±0.56 mmol/L before and 5.45±0.77 mmol/L on treatment with Patiromer (p<0.01). However, only 13 out of 37 patients (35%) reached a potassium level in the target range below 5.1 mmol/l.
Conclusion
With only 35% of patients in the potassium target range below 5.1 mmol/l, additional benefit of Patiromer under real-life conditions was small compared to OPAL-HK where 76% reached the target range.